Comparison the Effects of Etomidate and Sevoflurane During Electroconvulsive Therapy
Information source: Inonu University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Anesthesia; ECT
Intervention: Etomidate (Drug); Sevoflurane (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Inonu University Official(s) and/or principal investigator(s): Ulku Ozgul, MD, Study Director, Affiliation: Inonu University School of Medicine
Summary
The purpose of the study was to investigate the effects of etomidate or sevoflurane used in
electroconvulsive therapy (ECT) on duration of seizure, hemodynamic response and recovery
profiles.
Clinical Details
Official title: Ulku Ozgul, Associate Professor, Inonu University, Department of Anesthesiology and Reanimation
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Motor (EMG) seizure durationelectroencephalography (EEG) seizure duration
Secondary outcome: heart rate (HR),mean arterial pressure (MAP) recovery times
Detailed description:
Twenty-five patients will be a total of 150 ECT treatments in this prospective,
double-blinded, crossover study. Each patient will receive either 0. 2 mg/kg etomidate (Group
1) or 8% sevoflurane (Group 2) in 100% oxygen at 6 L/min fresh gas flow until loss of
consciousness for their initial electroconvulsive therapy session. In subsequent sessions,
patients will receive the alternative sevoflurane concentration and then alternated between
doses until the sixth session. Muscle paralysis will achieve with 1 mg/kg succinylcholine.
Motor (EMG) and electroencephalography seizure duration (EEG), heart rate (HR) and mean
arterial pressure (MAP) values, and recovery times will recorde.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Study include 25 patients of American Society of Anesthesiologists (ASA) physical
status I-II aged between 18-60 years who schedule for ECT sessions under general
anesthesia
Exclusion Criteria:
- Pregnancy
- Cerebrovascular disease
- Epilepsy
- Unstable cardiovascular disease
- Chronic obstructive pulmonary disease; and
- Renal or hepatic failure
Locations and Contacts
Additional Information
Starting date: July 2015
Last updated: July 15, 2015
|